Chronic kidney disease chronic kidney disease
Conditions
Interventions
3 x 2 capsules (or 2 x 3 capsules) containing potassium chloride (40 mmol),
potassium citrate (40 mmol) or placebo.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Adult patients with CKD stage 3b or 4 - Fall in eGFR > 2 ml/min/1.73 m2/year in preceding years - Hypertension (automated blood pressure > 140/90 mmHg or use of anti-hypertensive medication)
Exclusion criteria
Exclusion criteria: - Hyperkalemia (serum potassium > 5.5 mmol/l) at study visit V0 - Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers, potassium-sparing diuretics, or oral potassium binders. - Patients using calcineurin inhibitors - Patients using tolvaptan - Kidney transplant recipients - Patients with an active gastro-intestinal ulcus - Patients with previous history of ventricular cardiac arrhythmia - Patients with a life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year change in eGFR (renal outcome). | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects on 24-hour blood pressure, albuminuria, cardiovascular markers, and incidence of hyperkalemia | — |
Countries
Netherlands
Contacts
Public ContactM Atef Boulos Salib
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed